Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida

April 15, 2024

https://www.globenewswire.com/news-release/2024/04/15/2862631/0/en/Eagle-Pharmaceuticals-to-Present-Additional-Data-from-Phase-III-Trial-Demonstrating-Sustained-Response-of-Amisulpride-for-the-Rescue-Treatment-of-Postoperative-Nausea-and-Vomiting-.html

WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) — Eagle Pharmaceuticals, Inc. (Nasdaq:EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the sustained response of amisulpride for the rescue treatment of postoperative nausea and vomiting (“PONV”) will be presented at the upcoming American Society of PeriAnesthesia Nurses (ASPAN) 2024 National Conference, which is being held April 14-18, 2024, in Orlando, Florida.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.